Status:
COMPLETED
Feasibility of Blood Glucose Control With the Space TGC System in Postoperative Cardiac Surgery Patients in the ICU
Lead Sponsor:
B. Braun Melsungen AG
Conditions:
Critical Illness
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Hyperglycemia is common in critically ill patients and associated with an adverse outcome. Thus, glycaemic control is an important issue in critical care. Despite extensive efforts of the intensive ca...
Eligibility Criteria
Inclusion
- Inclusion:
- age: \> 18 years of age
- admitted following cardiac surgery
- stay in the ICU expected to be \> 20 h
- blood glucose \> 6.7 mmol/l within 4 hours of ICU admission or patient already on insulin treatment
- Exclusion:
- patients with hyperglycaemic crisis/ketoacidosis due to insulin deficiency.
- known or suspected allergy to insulin
- any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient (i.e., liver failure, other fatal organ failures)
- patients participating in another study
- moribund patients likely to die within 24 hours
- patients after organ transplantation within the last three months
- patients under high dose cortisol treatment (cortisol \> 1000 mg/day or equivalent doses of hydrocortisol)
Exclusion
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2011
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01233271
Start Date
November 1 2010
End Date
April 1 2011
Last Update
June 9 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Brompton Hospital, Intensive Care Medicine
London, United Kingdom, SW3 6NP